Genetic susceptibility to lymphoma

Haematologica

Volumn 92, Issue 7, 2007, Pages 960-969

  Skibola, Christine F ^a   Curry, John D ^a   Nieters, Alexandra ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Genetic susceptibility; Lymphoma; NHL; Polymorphisms; SNP

Indexed keywords

ALCOHOL; CASPASE; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CYTOKINE; DNA; FOLIC ACID; GLUTATHIONE TRANSFERASE T1; HLA ANTIGEN; HORMONE; INTERLEUKIN 10; SEX HORMONE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR;

ALCOHOL CONSUMPTION; ALLELE; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER GENETICS; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; CELL GROWTH; CELL SURVIVAL; DETOXIFICATION; DNA METHYLATION; DNA MODIFICATION; ENERGY METABOLISM; FOLATE METABOLISM; GENE; GENE DELETION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOMIC INSTABILITY; HODGKIN DISEASE; HORMONE METABOLISM; HORMONE SYNTHESIS; HUMAN; INFLAMMATION; INNATE IMMUNITY; LARGE CELL LYMPHOMA; LYMPHOMA; NONHODGKIN LYMPHOMA; OXIDATIVE STRESS; PENETRANCE; PROTEIN DOMAIN; PROTEIN FAMILY; SINGLE NUCLEOTIDE POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; REVIEW;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; LYMPHOMA; PENETRANCE; POLYMORPHISM, GENETIC;

EID: 34548776922     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11011     Document Type: Article

References (116)

1. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November, 1997. Hematol J 2000; 1:53-66.
2. Segel GB, Lichtman MA. Familial (inherited) leukemia, lymphoma, and myeloma: an overview. Blood Cells Mol Dis 2004;32:246-61.
3. Linet MS, Pottern LM. Familial aggregation of hematopoietic malignancies and risk of non-Hodgkin s lymphoma. Cancer Res 1992 Oct 1;52 Suppl 19:5468s-73s.
4. Houlston RS, Catovsky D, Yuille MR. Genetic susceptibility to chronic lymphocytic leukemia. Leukemia 2002;16:1008-14.
5. Goldin LR, Pfeiffer RM, Li X, Hemminki K. Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database. Blood 2004;104:1850-4.
6. Chang ET, Smedby KE, Hjalgrim H, Porwit-MacDonald A, Roos G, Glimelius B, et al. Family history of hematopoietic malignancy and risk of lymphoma. J Natl Cancer Inst 2005;97:1466-74.
7. Altieri A, Bermejo JL, Hemminki K. Familial risk for non-Hodgkin lymphoma and other lymphoproliferative malignancies by histopathologic subtype: the Swedish Family-Cancer Database. Blood 2005;106:668-72.
8. Willis TG, Dyer MJ. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood 2000;96:808-22.
9. Shen M, Zheng T, Lan Q, Zhang Y, Zahm SH, Wang SS, et al. Polymorphisms in DNA repair genes and risk of non-Hodgkin lymphoma among women in Connecticut. Hum Genet 2006;119:659-68.
10. Hill DA, Wang SS, Cerhan JR, Davis S, Cozen W, Severson RK, et al. Risk of non-Hodgkin lymphoma (NHL) in relation to germline variation in DNA repair and related genes. Blood 2006;.
11. Smedby KE, Linderen CM, Hjalgrim H, Humphreys K, Schollkopf C, Chang ET, et al. Variation in DNA repair genes ERCC2, XRCC1, and XRCC3 and risk of follicular lymphoma. Cancer Epidemiol Biomarkers Prev 2006;15:258-65.
12. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:1513-30.
13. Mino C, Fiallo BF, Morillo SA, Acosta A, Gimenez P, Ocampo L, et al. Analysis of the polymorphism [gIVS12-6T > C] in the hMSH2 gene in lymphoma and leukemia. Leuk Lymphoma 2003;44:505-8.
14. Hishida A, Matsuo K, Hamajima N, Ito H, Ogura M, Kagami Y, et al. Polymorphism in the hMSH2 gene (gIVS 12-6T->C) and risk of non-Hodgkin lymphoma in a Japanese population. Cancer Genet Cytogenet 2003;147:71-4.
15. Ushmorov A, Leithauser F, Sakk O, Weinhausel A, Popov SW, Moller P, et al. Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood 2006;107:2493-500.
16. Galm O, Herman JG, Baylin SB. The fundamental role or epigenetics in hematopoietic malignancies. Blood Rev 2006;20:1-13.
17. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-3.
18. Skibola CF, Forrest MS, Coppede F, Agana L, Hubbard A, Smith MT, et al. Polymorphisms and haplotypes in folate-metabolizing genes and risk of non-Hodgkin lymphoma. Blood 2004;104:2155-62.
19. Lightfoot TJ, Skibola CF, Willett EV, Skibola DR, Allan JM, Coppede F, et al. Risk of non-Hodgkin lymphoma associated with polymorphisms in folate-metabolizing genes. Cancer Epidemiol Biomarkers Prev 2005;14:2999-3003.
20. Matsuo K, Hamajima N, Suzuki R, Ogura M, Kagami Y, Taji H, et al. Methylenetetrahydrofolate reductase gene (MTHFR) polymorphisms and reduced risk of malignant lymphoma. Am J Hematol 2004; 77: 351-7.
21. Gemmati D, Ongaro A, Scapoli GL, Delia PM, Tognazzo S, Serino ML, et al. Common gene polymorphisms in the metabolic folate and methylation pathway and the risk of acute lymphoblastic leukemia and non-Hodgkin's lymphoma in adults. Cancer Epidemiol Biomarkers Prev 2004;13:787-94.
22. Toffoli G, Rossi D, Gaidano G, Cecchin E, Boiocchi M, Carbone A. Methylenetetrahydrofolate reductase genotype in diffuse large B-cell lymphomas with and without hypermethylation of the DNA repair gene 06-methylguanine DNA methyltransferase. Int J Biol Markers 2003;18:218-21.
23. Rudd MF, Sellick GS, Allinson R, Matutes E, Catovsky D, Houlston RS. MTHFR polymorphisms and risk of chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev 200;13:2268-70.
24. Lincz LF, Scorgie FE, Kerridge I, Potts R, Spencer A, Enno A. Methionine synthase genetic polymorphism MS A2756G alters susceptibility to follicular but not diffuse large B-cell non-Hodgkin's lymphoma or multiple myeloma. Br J Haematol 2003; 120:1051-4.
25. Linnebank M, Schmidt S, Kölsch H, Linnebank A, Heun R, Schmidt-Wolf IG, et al. The methionine synthase polymorphism D919G alters susceptibility to primary central nervous system lymphoma. Br J Cancer 2004;90:1969-71.
26. Niclot S, Pruvot Q, Besson C, Savoy D, Macintyre E, Salles G, et al Implication of the folate-methionine metabolism pathways in susceptibility to follicular lymphomas. Blood 2006;108:278-85.
27. Hori T, Ayusawa D, Shimizu K, Koyama H, Seno T. Assignment of human gene encoding thymidylate synthase to chromosome 18 using interspecific cell hybrids between thymidylate synthase-negative mouse mutant cells and human diploid fibroblasts. Somat Cell Mol Genet 1985;11:277-83.
28. Hori T, Ayusawa D, Shimizu K, Koyama H, Seno T. Chromosome breakage induced by thymidylate stress in thymidylate synthase-negative mutants of mouse FM3A cells. Cancer Res 1984;44:703-9.
29. Hishida A, Matsuo K, Hamajima N, Ito H, Ogura M, Kagami Y, et al. Associations between polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and susceptibility to malignant lymphoma. Haematologica 2003; 88:159-66.
30. Matsuo K, Suzuki R, Hamajima N, Ogura M, Kagami Y, Taji H, et al. Association between polymorphisms of folate- and methionine-metabolizing enzymes and susceptibility to malignant lymphoma. Blood 2001;97:3205-9.
31. Karin M, Cao Y, Greten FR, Li ZW. NF-kB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-10.
32. Rothman N, Skibola CF, Wang SS, Morgan G, Lan Q, Smith MT, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 2006;7:27-38.
33. Karin M, Greten FR. NF-kB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005;5:749-59.
34. Allen RD. Polymorphism of the human TNF-alpha promoter-random variation or functional diversity? Mol Immunol 1999;36:1017-27.
35. Bayley JP, Ottenhoff TH, Verweij CL. Is there a future for TNF promoter polymorphisms? Genes Immun 2004;5:315-29.
36. Spink CF, Keen LJ, Mensah FK, Law GR, Bidwell JL, Morgan GJ. Association between non-Hodgkin lymphoma and haplotypes in the TNF region. Br J Haematol 2006;133:293-300.
37. Lan Q, Zheng T, Rothman N, Zhang Y, Wang SS, Shen M, et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 2006; 107:4101-8.
38. Wang SS, Cerhan JR, Hartge P, Davis S, Cozen W, Severson RK, et al. Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Cancer Res 2006; 66:9771-80.
39. Purdue MP, Lan Q, Kricker A, Grulich AE, Vajdic CM, Turner J, et al. Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin lymphoma study. Carcinogenesis 2007;28:704-12.
40. Hellmig S, Fischbach W, Goebeler-Kolve ME, Folsch UR, Hampe J, Schreiber S. A functional promotor polymorphism of TNF-alpha is associated with primary gastric B-Cell lymphoma. Am J Gastroenterol 2005;100:2644-9.
41. Wu MS, Chen LT, Shun CT, Huang SP, Chiu HM, Wang HP, et al. Promoter polymorphisms of tumor necrosis factor-alpha are associated with risk of gastric mucosa-associated lymphoid tissue lymphoma. Int J Cancer 2004;110:695-700.
42. Tsukasaki K, Miller CW, Kubota T, Takeuchi S, Fujimoto T, Ikeda S, et al. Tumor necrosis factor alpha polymorphism associated with increased susceptibility to development of adult T-cell leukemia/lymphoma in human T-lymphotropic virus type 1 carriers. Cancer Res 2001;61:3770-4.
43. Cozen W, Gill PS, Ingles SA, Masood R, Martinez-Maza O, Cockbum MG, et al. IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma. Blood 2004;103:3216-21.
44. Cordano P, Lake A, Shield L, Taylor GM, Alexander FE, Taylor PR, et al. Effect of IL-6 promoter polymorphism on incidence and outcome in Hodgkin's lymphoma. Br J Haematol 2005;128:493-5.
45. Zheng C, Huang DR, Bergenbrant S, Sundblad A, Osterborg A, Bjorkholm M, et al. Interleukin 6, tumour necrosis factor alpha, interleukin 1b and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. Br J Haematol 2000;10:39-45.
46. Hulkkonen J, Vilpo J, Vilpo L, Koski T, Hurme M. Interleukin-1b, interleukin-1 receptor antagonist and interleukin-6 plasma levels and cytokine gene polymorphisms in chronic lymphocytic leukemia: correlation with prognostic parameters. Haematologica 2000;85:600-6.
47. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998;102:1369-76.
48. Foster CB, Lehrnbecher T, Samuels S, Stein S, Mol F, Metcalf JA, et al. An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus. Blood 2000; 96: 2562-7.
49. Hegedus CM, Skibola CF, Bracci PM, Holly EA, Smith MT. Screening the human serum proteome for genotype-phenotype associations: An analysis of the IL6-174G>C polymorphism. Proteomics 2007;7:548-57.
50. Chamaillard M, Philpott D, Girardin SE, Zouali H, Lesage S, Chareyre F, et al. Gene-environment interaction modulated by allelic heterogeneity in inflammatory diseases. Proc Natl Acad Sci USA 2003;100:3455-60.
51. Yamada R, Ymamoto K. Recent findings on genes associated with inflammatory disease. Mutat Res 2005;573:136-51.
52. Forrest MS, Skibola CF, Lightfoot TJ, Bracci PM, Willett EV, Smith MT, et al. Polymorphisms in innate immunity genes and risk of non-Hodgkin lymphoma. Br J Haematol 2006; 134:180-3.
53. Rosenstiel P, Hellmig S, Hampe J, Ott S, Till A, Fischbach W, et al. Influence of polymorphisms in the NOD1/CARD4 and NOD2/CARD15 genes on the clinical outcome of Helicobacter pylori infection. Cell Microbiol 2006; 8: 1188-98.
54. Wehkamp J, Schmid M, Fellermann K, Stange EF. Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's disease. J Leukoc Biol 2005;77:460-5.
55. Hellmig S, Fischbach W, Goebeler-Kolve ME, Folsch UR, Hampe J, Schreiber S. Association study of a functional Toll-like receptor 4 polymorphism with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. Leuk Lymphoma 2005;46:869-72.
56. Nieters A, Beckmann L, Deeg E, Becker N. Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. Genes Immun 2006; 7:615-24.
57. Salmon JE, Millard S, Schachter LA, Arnett FC, Ginzler EM, Gourley MF, et al. Feg RIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest 1996;97:1348-54.
58. Hogarth PM. Fc receptors are major mediators of antibody based inflammation in autoimmunity. Curr Opin Immunol 2002;14:798-802.
59. Shen J, Wang RT, Wang LW, Xu YC, Wang XR. A novel genetic polymorphism of inducible nitric oxide synthase is associated with an increased risk of gastric cancer. World J Gastroenterol 2004;10:3278-83.
60. Wang SS, Davis S, Cerhan JR, Hartge P, Severson RK, Cozen W, et al. Polymorphisms in oxidative stress genes and risk for non-Hodgkin lymphoma. Carcinogenesis 2006; 27:1828-34.
61. Hiroi S, Harada H, Nishi H, Satoh M, Nagai R, Kimura A. Polymorphisms in the SOD2 and HLA-DRB1 genes are associated with nonfamilial idiopathic dilated cardiomyopathy in Japanese. Biochem Biophys Res Commun 1999;261:332-9.
62. Lightfoot T, Skibola CF, Adamson P, Forest M, Smith A, Morgan G, et al. Polymorphisms in the oxidative stress genes, superoxide dismutase, glutathione peroxidase and catalase and risk of non-Hodgin lymphoma. Haematologica 2006;91:1222-7.
63. Skibola CF. Obesity, diet and risk of non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev 2007;16:392-5.
64. Bedoui S, Kawamura N, Straub RH, Pabst R, Yamamura T, von Horsten S. Relevance of neuropeptide Y for the neuroimmune crosstalk. J Neuroimmunol 2003;134:1-11.
65. Dixit VD, Schaffer EM, Pyle RS, Collins GD, Sakthivel SK, Palaniappan R, et al. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest 2004;114:57-66.
66. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005;115:911-9.
67. Skibola CF, Holly EA, Forrest MS, Hubbard A, Bracci PM, Skibola DR, et al. Body mass index, leptin and leptin receptor polymorphisms, and non-hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 2004; 13:779-86.
68. Willett EV, Skibola CF, Adamson P, Skibola DR, Morgan GJ, Smith MT, et al. Non-Hodgkin's lymphoma, obesity and energy homeostasis polymorphisms. Br J Cancer 2005;93:811-6.
69. Skibola DR, Smith MT, Bracci PM, Hubbard AE, Agana L, Chi S, et al. Polymorphisms in ghrelin and neuropeptide Y genes are associated with non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 2005;14:1251-6.
70. Ding B. Distribution of the NPY 1128C allele frequency in different populations. J Neural Transm 2003;110:1199-204.
71. Gado K, Rimanoczi E, Hasitz A, Gigler G, Toth BE, Nagy GM, et al. Elevated levels or serum prolactin in patients with advanced multiple myeloma. Neuroimmunomodulation 2001; 9:231-6.
72. Hooghe R, Merchav S, Gaidano G, Naessens F, Matera L. A role for growth hormone and prolactin in leukaemia and lymphoma? Cell Mol Life Sci 1998;54:1095-101.
73. Skibola CF, Bracci PM, Paynter RA, Forrest MS, Agana L, Woodage T, et al. Polymorphisms and haplotypes in the cytochrome P450 17A1, prolactin, and catechol-O-methyltransferase genes and non-Hodgkin lymphoma risk. Cancer Epidemiol Biomarkers Prev 2005;14:2391-401.
74. Skibola CF, Lightfoot T, Agana L, Smith A, Rollinson S, Kao A, et al. Polymorphisms in cytochrome P450 17A1 and risk of non-Hodgkin lymphoma. Br J Haematol 2005;129: 618-21.
75. Sharp L, Cardy AH, Cotton SC, Little J. CYP17 gene polymorphisms: prevalence and associations with hormone levels and related factors, a HuGE review. Am J Epidemiol 2004;160:729-40.
76. Kerridge I, Lincz L, Scorgie F, Hickey D, Granter N, Spencer A. Association between xenobiotic gene polymorphisms and non-Hodgkin's lymphoma risk. Br J Haematol 2002; 118:477-81.
77. RoUinson S, Levene AP, Mensah FK, Roddam PL, Allan JM, Diss TC, et al. Gastric marginal zone lymphoma is associated with polymorphisms in genes involved in inflammatory response and antioxidative capacity. Blood 2003;102:1007-11.
78. Hohaus S, Massini G, D'Alo' F, Guidi F, Putzulu R, Scardocci A, et al. Association between glutathione S-transferase genotypes and Hodgkin's lymphoma risk and prognosis. Clin Cancer Res 2003;9:3435-40
79. Wu MS, Shun CT, Huang SP, Cheng AL, Chen LT, Lin JT. Effect of interleukin-1b and glutathione S-transferase genotypes on the development of gastric mucosa-associated lymphoid tissue lymphoma. Haematologica 2004;89:1015-7.
80. Sarmanova J, Benesova K, Gut I, Nedelcheva-Kristensen V, Tynkova L, Soucek P. Genetic polymorphisms of biotransformation enzymes in patients with Hodgkin's and non-Hodgkin's lymphomas. Hum Mol Genet 2001;10:1265-73.
81. Chiu BC, Kolar C, Gapstur SM, Lawson T, Anderson JR, Weisenburger DD. Association of NAT and GST polymorphisms with non-Hodgkin's lymphoma: a population-based case-control study. Br J Haematol 2005;128:610-5.
82. Costa LG, Cole TB, Jarvik GP, Furlong CE. Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med 2003; 54:371-92.
83. Mackness B, Durrington P, Povey A, Thomson S, Dippnall M, Mackness M, et al. Paraoxonase and susceptibility to organophosphorus poisoning in farmers dipping sheep. Pharmacogenetics 2003;13:81-8.
84. Khalsa SB, Ralph MR, Block GD. Chloride conductance contributes to period determination of a neuronal circadian pacemaker. Brain Res 1990;520:166-9.
85. Morton LM, Schenk M, Hein DW, Davis S, Zahm SH, Cozen W, et al. Genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2) and risk of non-Hodgkin lymphoma. Pharmacogenet Genomics 2006; 16: 537-45.
86. Lemos MC, Cabrita FJ, Silva HA, Vivan M, Placido F, Regateiro FJ. Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias. Carcinogenesis 1999;20:1225-9.
87. Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium. Nature 1999; 401:921-3.
88. Diepstra A, Niens M, Vellenga E, van Imhoff GW, Nolte IM, Schaapveld M, et al. Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin s lymphoma. Lancet 2005;365:2216-24.
89. Klitz W, Aldrich CL, Fildes N, Horning SJ, Begovich AB. Localization of predisposition to Hodgkin disease in the HLA class II region. Am J Hum Genet 1994; 54: 497-505.
90. Alexander FE, Jarrett RF, Cartwright RA, Armstrong AA, Gokhale DA, Kane E, et al. Epstein-Barr Virus and HLA-DPB1-*0301 in young adult Hodgkin's disease: evidence for inherited susceptibility to Epstein-Barr virus in cases that are EBV(+ve). Cancer Epidemiol Biomarkers Prev 2001;10:705-9.
91. Harty LC, Lin AY, Goldstein AM, Jaffe ES, Carrington M, Tucker MA, et al. HLA-DR, HLA-DQ, and TAP genes in familial Hodgkin disease. Blood 2002;99:690-3.
92. Nathalang O, Tatsumi N, Hino M, Prayoonwiwat W, Yamane T, Suwanasophon C, et al. HLA class II polymorphism in Thai patients with non-Hodgkin's lymphoma. Eur J Immunogenet 1999;26:389-92.
93. Al Tonbary Y, Abdel-Razek N, Zaghloul H, Metwaly S, El Deek B, El Shawaf R. HLA class II polymorphism in Egyptian children with lymphomas. Hematology 2004; 9: 139-45.
94. Sellick GS, Webb EL, Allinson R, Matutes E, Dyer MJ, Jonsson V, et al. A high-density SNP genomewide linkage scan for chronic lymphocytic leukemia-susceptibility loci. Am J Hum Genet 2005;77:420-9.
95. Goldin LR, McMaster ML, Ter Minassian M, Saddlemire S, Harmsen B, Lalonde G, et al. A genome screen of families at high risk for Hodgkin lymphoma: evidence for a susceptibility gene on chromosome 4. J Med Genet 2005;42:595-601.
96. Steffen J, Varon R, Mosor M, Maneva G, Maurer M, Stumm M, et al. Increased cancer risk of heterozygotes with NBS1 germline mutations in Poland. Int J Cancer 2004; 111:67-71.
97. Hishida A, Matsuo K, Tajima K, Ogura M, Kagami Y, Taji H, et al. Polymorphisms of p53 Arg72Pro, p73 G4C14-to-A4T14 at exon 2 and p21 Ser31Arg and the risk of non-Hodgkin's lymphoma in Japanese. Leuk Lymphoma 2004;45:957-64.
98. Chouchane L, Ahmed SB, Baccouche S, Remadi S. Polymorphism in the tumor necrosis factor-alpha promoter region and in the heat shock protein 70 genes associated with malignant tumors. Cancer 1997;80:1489-96.
99. Demeter J, Porzsolt F, Ramisch S, Schmid M, Messer G. Polymorphism of the tumour necrosis factor-a and lymphotoxin-alpha genes in hairy cell leukaemia. Br J Haematol 1997;97:132-4.
100. Bel Hadj Jrad B, Chatti A, Laatiri A, Ahmed SB, Romdhane A, Ajimi S, et al. Tumor necrosis factor promoter gene polymorphism associated with increased susceptibility to non-Hodgkin's lymphomas. Eur J Haematol 2007; 78:117-22.
101. Fitzgibbon J, Grenzelias D, Matthews J, Lister TA, Gupta RK. Tumour necrosis factor polymorphisms and susceptibility to follicular lymphoma. Br J Haematol 1999;107:388-91.
102. Matsuo K, Hamajima N, Suzuki R, Nakamura S, Seto M, Morishima Y, et al. No substantial difference in genotype frequencies of interleukin and myeloperoxidase polymorphisms between malignant lymphoma patients and non-cancer controls. Haematologica 2001; 86: 602-8.
103. Vasku JA, Vasku A, Goldbergova M, Vasku V. Heterozygote AG variant of -596 A/G IL-6 gene polymorphism is a marker for cutaneous T-cell lymphoma (CTCL). Clin Immunol 2004;113:256-60.
104. Breen EC, Boscardin WJ, Detels R, Jacobson LP, Smith MW, O'Brien SJ, et al. Non-Hodgkin's B cell lymphoma in persons with acquired immunodeficiency syndrome is associated with increased serum levels of IL10, or the IL10 promoter -592 C/C genotype. Clin Immunol 2003;109:119-29.
105. Cunningham LM, Chapman C, Dunstan R, Bell MC, Joske DJ. Polymorphisms in the interleukin 10 gene promoter are associated with susceptibility to aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2003;44:251-5.
106. Lech-Maranda E, Baseggio L, Bienvenu J, Chariot C, Berger F, Rigal D, et al. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-ce lymphoma. Blood 2004; 103: 3529-34.
107. Dean M, Jacobson LP, McFarlane G, Margolick JB, Jenkins FJ, Howard OM, et al. Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-d32 mutation. Cancer Res 1999;59:3561-4.
108. Rabkin CS, Yang Q, Goedert JJ, Nguyen G, Mitsuya H, Sei S. Chemokine and chemokine receptor gene variants and risk of non-Hodgkin's lymphoma in human immunodeficiency virus-1-infected individuals. Blood 1999;93:1838-42.
109. De Roos AJ, Gold LS, Wang S, Hartge P, Cerhan JR, Cozen W, et al. Metabolic gene variants and risk of non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev 2006; 15:1647-53.
110. Wang SS, Cozen W, Severson RK, Hartge P, Cerhan JR, Davis S, et al. Cyclin D1 splice variant and risk for non-Hodgkin lymphoma. Hum Genet 2006;120:297-300.
111. Lossos IS, Jones CD, Zehnder JL, Levy R. A polymorphism in the BCL-6 gene is associated with follicle center lymphoma. Leuk Lymphoma 2001;42:1343-50.
112. Zhang Y, Lan Q, Rothman N, Zhu Y, Zahm SH, Wang SS, et al. A putative exonic splicing polymorphism in the BCL6 gene and the risk of non-Hodgkin lymphoma. J Natl Cancer Inst 2005;97:1616-8.
113. Lan Q, Zheng T, Chanock S, Zhang Y, Shen M, Wang SS, et al. Genetic variants in caspase genes and susceptibility to non-Hodgkin's lymphoma. Carcinogenesis 2007; 28: 823-7.
114. Piras G, Monne M, Uras A, Palmas A, Murineddu M, Arru L, et al. Genetic analysis of the 2q33 region containing CD28-CTLA4-ICOS genes: association with non-Hodgkin's lymphoma. Br J Haematol 2005;129:784-90.
115. Cheng TY, Lin JT, Chen LT, Shun CT, Wang HP, Lin MT, et al. Association of T-cell regulatory gene polymorphisms with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2006;24:3483-9.
116. Zhu Y, Leaderer D, Guss C, Brown HN, Zhang Y, Boyle P, et al. Ala394Thr polymorphism in the clock gene NPAS2: A circadian modifier for the risk of non-Hodgkin's lymphoma. Int J Cancer 2007;120:432-5.